The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. https://dillanxpnw010961.bimmwiki.com/11461997/glp_3_retatrutide_a_comparative_analysis